ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in the Phase Ib/II clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of non-small cell lung cancer was successfully dosed, according to a Monday filing with the Hong Kong bourse.
IMM2510 is a bispecific molecule developed by the group that uses a mAbTrap structure to target two proteins: VEGF, which promotes blood vessel growth, and PD-L1, which suppresses the immune system, reducing blood flow to tumors and leads to their shrinking, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.